Acumen Research and Consulting Recombinant Plasma Protein Therapeutics Market | Page 12

12.3.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 12.4. Egypt 12.4.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 12.4.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 12.4.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) 12.5. Rest of Africa 12.5.1. Market Revenue and Forecast By Drug Class, 2015 – 2026 ($Million) 12.5.2. Market Revenue and Forecast By Cell Line, 2015 – 2026 ($Million) 12.5.3. Market Revenue and Forecast By Indication, 2015 – 2026 ($Million) CHAPTER 13. COMPANY PROFILE 13.1. Octapharma 13.1.1. Company Snapshot 13.1.2. Overview 13.1.3. Financial Overview 13.1.4. Type Portfolio 13.1.5. Key Developments 13.1.6. Strategies 13.2. Novo Nordisk A / S 13.2.1. Company Snapshot 13.2.2. Overview 13.2.3. Financial Overview 13.2.4. Type Portfolio 13.2.5. Key Developments 13.2.6. Strategies 13.3. Bayer AG 13.3.1. Company Snapshot 13.3.2. Overview 13.3.3. Financial Overview 13.3.4. Type Portfolio 13.3.5. Key Developments 13.3.6. Strategies Would like to place an order or any question, please feel free to contact at [email protected] | [phone]